EUR 0.44
(0.0%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 15.35 Million EUR | 39.35% |
2022 | 11.01 Million EUR | 14.69% |
2021 | 9.6 Million EUR | -39.36% |
2020 | 15.84 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 13.99 Million EUR | 0.0% |
2024 Q1 | 13.99 Million EUR | -8.84% |
2023 FY | 15.35 Million EUR | 39.35% |
2023 Q3 | 15.35 Million EUR | -11.19% |
2023 Q1 | 17.28 Million EUR | 56.91% |
2023 Q4 | 15.35 Million EUR | 0.0% |
2023 Q2 | 17.28 Million EUR | 0.0% |
2022 Q4 | 11.01 Million EUR | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Nicox S.A. | 25.15 Million EUR | 38.958% |
European Medical Solutions | 18.13 Million EUR | 15.316% |
argenx SE | 18.1 Million EUR | 15.196% |
BioSenic S.A. | 28.16 Million EUR | 45.478% |
Celyad Oncology SA | 902 Thousand EUR | -1602.217% |
Hyloris Pharmaceuticals SA | 5.29 Million EUR | -190.026% |
Onward Medical N.V. | 16.87 Million EUR | 9.008% |
Oxurion NV | 12.33 Million EUR | -24.485% |
PHAXIAM Therapeutics S.A. | 10.19 Million EUR | -50.544% |
Financière de Tubize SA | 79.2 Million EUR | 80.614% |
UCB SA | 3.03 Billion EUR | 99.495% |